Arcus Biosciences (RCUS) Set to Announce Quarterly Earnings on Wednesday

Arcus Biosciences (NYSE:RCUS) will be posting its quarterly earnings results after the market closes on Wednesday, November 6th. Analysts expect Arcus Biosciences to post earnings of ($1.07) per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

Arcus Biosciences (NYSE:RCUS) last announced its earnings results on Thursday, August 8th. The company reported ($1.02) earnings per share for the quarter, hitting the consensus estimate of ($1.02). Arcus Biosciences had a negative net margin of 100.81% and a negative return on equity of 42.86%. The company had revenue of $39.00 million during the quarter, compared to analyst estimates of $26.24 million. During the same quarter last year, the firm posted ($1.04) earnings per share. Arcus Biosciences’s revenue was up 34.5% compared to the same quarter last year. On average, analysts expect Arcus Biosciences to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Arcus Biosciences Stock Performance

Shares of RCUS stock opened at $15.50 on Monday. Arcus Biosciences has a one year low of $12.95 and a one year high of $20.31. The firm’s 50 day moving average price is $16.73 and its 200-day moving average price is $16.01. The firm has a market cap of $1.42 billion, a P/E ratio of -5.02 and a beta of 0.89.

Wall Street Analyst Weigh In

RCUS has been the subject of a number of research reports. Wedbush reaffirmed an “outperform” rating and issued a $30.00 price objective on shares of Arcus Biosciences in a research note on Thursday, October 3rd. Barclays increased their price target on shares of Arcus Biosciences from $25.00 to $29.00 and gave the stock an “overweight” rating in a research report on Friday, October 25th. Evercore ISI upgraded shares of Arcus Biosciences to a “strong-buy” rating in a report on Friday, August 9th. HC Wainwright began coverage on shares of Arcus Biosciences in a report on Monday, October 21st. They set a “neutral” rating and a $20.00 target price on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Arcus Biosciences in a research note on Thursday, October 3rd. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Arcus Biosciences presently has an average rating of “Buy” and an average price target of $33.67.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.